Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries and affiliates or offices in five countries.
![Novo Nordisk logo](/files/LOGO/353278-NVO.png)
Company profile
Ticker
NVO, NONOF
Exchange
Website
CEO
Lars Fruergaard Joergensen
Employees
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
NVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
25 Jul 24
6-K
Current report (foreign)
22 Jul 24
6-K
Current report (foreign)
15 Jul 24
6-K
Current report (foreign)
11 Jul 24
6-K
Current report (foreign)
9 Jul 24
6-K
Current report (foreign)
2 Jul 24
6-K
Current report (foreign)
26 Jun 24
6-K
Current report (foreign)
24 Jun 24
6-K
Current report (foreign)
17 Jun 24
6-K
Current report (foreign)
10 Jun 24
Latest ownership filings
11-K
Annual report of employee stock purchases
21 Jun 24
11-K
Annual report of employee stock purchases
21 Jun 24
SC 13G/A
BlackRock Inc.
6 Feb 24
11-K
Annual report of employee stock purchases
27 Jun 23
11-K
Annual report of employee stock purchases
27 Jun 23
SC 13G/A
BlackRock Inc.
23 Feb 23
11-K
Annual report of employee stock purchases
28 Jun 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
1 Feb 22
11-K
Annual report of employee stock purchases
23 Jun 21
Financial summary
Quarter (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
9.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1667 |
Opened positions | 501 |
Closed positions | 102 |
Increased positions | 597 |
Reduced positions | 396 |
13F shares | Current |
---|---|
Total value | 35.83 tn |
Total shares | 321.46 mm |
Total puts | 4.93 mm |
Total calls | 5.29 mm |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Jennison Associates | 21.08 mm | $2.71 tn |
FMR | 17.60 mm | $2.26 tn |
Fisher Asset Management | 13.72 mm | $1.76 tn |
BAC Bank Of America | 13.05 mm | $1.68 tn |
MS Morgan Stanley | 12.01 mm | $1.54 tn |
Fayez Sarofim & Co | 11.82 mm | $1.52 tn |
Renaissance Technologies | 10.79 mm | $1.38 bn |
Loomis Sayles & Co L P | 8.85 mm | $1.14 bn |
Folketrygdfondet | 8.76 mm | $1.12 tn |
T. Rowe Price | 8.59 mm | $1.10 bn |
News
Novo Nordisk Unusual Options Activity For July 26
26 Jul 24
Novo Nordisk Shares Decline Amid Competitive Pressure
25 Jul 24
Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know
25 Jul 24
Novo Nordisk's Options Frenzy: What You Need to Know
25 Jul 24
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
24 Jul 24
Press releases
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development
11 Jun 24
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
4 Jun 24
Novo Nordisk launches national Wegovy® campaign, Power of Wegovy®
3 Jun 24
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
29 May 24
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
21 May 24